Skip to main content
logo
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
21.71
-0.50 (-2.25%)
At close: Mar 12, 2026, 4:00 PM EDT
21.51
-0.20 (-0.92%)
Pre-market: Mar 13, 2026, 6:00 AM EDT

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
North America Revenue
377.00M340.46M
North America Revenue Growth
10.73%10.85%
Latin America Revenue
170.00M130.71M
Latin America Revenue Growth
30.06%69.01%
Europe Revenue
108.00M80.12M
Europe Revenue Growth
34.79%68.56%
Asia-Pacific Revenue
18.00M8.93M
Asia-Pacific Revenue Growth
101.57%301.53%
Revenue (Other)
--230.00K
Revenue (Total)
673.00M560.00M
Revenue (Total) Growth
20.18%29.03%

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Crysvita Revenue
177.00M134.71M
Crysvita Revenue Growth
31.39%77.96%
Dojolvi Revenue
96.00M88.19M
Dojolvi Revenue Growth
8.85%24.86%
Evkeeza Revenue
59.00M32.16M
Evkeeza Revenue Growth
83.45%783.09%
Mepsevii Revenue
37.00M30.35M
Mepsevii Revenue Growth
21.91%-0.30%
Total Product Revenue
369.00M285.42M
Total Product Revenue Growth
29.29%58.20%
Crysvita Royalty Revenue
304.00M274.82M
Crysvita Royalty Revenue Growth
10.62%50.46%
Revenue (Other)
--230.00K
Revenue (Total)
673.00M560.00M
Revenue (Total) Growth
20.18%29.03%
Updated Feb 12, 2026. Data Source: Fiscal.ai.